Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and $44 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) saying the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE